A 52-year-old man with a 10-year history of type 2 diabetes mellitus presents to the nephrology clinic. His blood pressure is 148/92 mmHg despite amlodipine 5 mg daily. Serum creatinine is 2.8 mg/dL (baseline 1.2 mg/dL 2 years ago), eGFR is 28 mL/min/1.73m², and urine albumin-to-creatinine ratio (UACR) is 450 mg/g. Urinalysis shows 2+ proteinuria. Renal ultrasound shows normal-sized kidneys with increased echogenicity. Which of the following is the most appropriate next step in management to slow progression of his chronic kidney disease?

Explanation

## Clinical Context This patient has CKD stage 3b (eGFR 28 mL/min/1.73m²) secondary to diabetic nephropathy, evidenced by: - Progressive rise in serum creatinine over 2 years - Albuminuria (UACR 450 mg/g, indicating overt proteinuria) - Hypertension - Sonographic changes (increased echogenicity) ## Renoprotective Strategy in Diabetic CKD **Key Point:** The dual approach of SGLT2 inhibitors + ACE/ARB + blood pressure control is now the gold standard for slowing CKD progression in diabetes, supported by landmark trials (DAPA-CKD, EMPA-KIDNEY). **High-Yield:** SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce CKD progression and cardiovascular events independent of glycemic control. They are now recommended as first-line agents in diabetic CKD even in non-diabetics with CKD. ## Why Option B is Correct 1. **SGLT2 inhibitor initiation:** Provides: - Reduction in intraglomerular pressure - Natriuresis and reduced glomerular hyperfiltration - Cardiovascular and renal protection (30% reduction in doubling of serum creatinine in DAPA-CKD) - Benefit independent of baseline eGFR (effective even at eGFR <30) 2. **Blood pressure target <130/80 mmHg:** Current guidelines (KDIGO 2021) recommend systolic BP <120 mmHg in CKD with albuminuria for optimal renoprotection. 3. **Timing:** At eGFR 28, this is the ideal window to initiate disease-modifying therapy before progression to ESRD. ## Comparative Renoprotective Agents | Agent | Mechanism | Evidence | Timing in CKD | |-------|-----------|----------|---------------| | ACE inhibitor/ARB | Efferent arteriole vasodilation | Reduces proteinuria, slows progression | First-line, but now combined with SGLT2i | | SGLT2 inhibitor | Reduced glomerular hyperfiltration, natriuresis | DAPA-CKD, EMPA-KIDNEY: 30–40% reduction in CKD progression | Now preferred, added to ACE/ARB | | GLP-1 RA | Weight loss, BP reduction, anti-inflammatory | Secondary renal benefit; not primary CKD therapy | Adjunct if diabetic | | Loop diuretic | Symptom relief only | No renoprotection; may worsen renal function if volume-depleted | Reserved for edema/fluid overload | **Clinical Pearl:** SGLT2 inhibitors work synergistically with ACE/ARB and should not be withheld due to eGFR <30; they are effective across all stages of CKD. ## Why Dialysis Is Not Yet Indicated At eGFR 28 mL/min/1.73m², the patient is not yet at ESRD (eGFR <15). Dialysis initiation is typically considered at eGFR <15 or when symptomatic uremia develops. Premature dialysis initiation increases cardiovascular morbidity. [cite:KDIGO 2021 Clinical Practice Guideline for CKD], [cite:Harrison 21e Ch 279]